Northway Biotech Unveils €61M Lithuanian Facility to Industrialize CAR-T, Integrating Vector Supply for Next-Gen Therapies

September 13, 2026

Invest Lithuania Lithuania

Overview

Northway Biotech has inaugurated a €61 million, 3,500 sq. meter CDMO facility in Vilnius, Lithuania, designed to industrialize the manufacturing of allogeneic CAR-T and other advanced cell and gene therapies. Featuring up to 20 segregated cGMP lines, the facility integrates viral vector supply from an adjacent gene therapy center, ensuring end-to-end production. This strategic expansion significantly boosts Europe’s capacity for advanced personalized medicine, positioning Northway Biotech as a key player in scaling next-generation therapeutic solutions globally.

In Depth

Background

The cell and gene therapy sector is experiencing exponential growth, driving a burgeoning demand for specialized manufacturing capacities that adhere to stringent cGMP (Current Good Manufacturing Practice) requirements. CAR-T cell therapies, in particular, necessitate complex production processes and significant capital investment. Northway Biotech’s new facility directly addresses this critical market need, bolstering Europe’s advanced therapy manufacturing infrastructure. The CDMO (Contract Development and Manufacturing Organization) model offers biopharmaceutical companies a strategic avenue to outsource capital-intensive manufacturing, thereby enabling them to focus on core research and development while ensuring high-quality, compliant production. This expansion also reinforces Lithuania’s emerging role as a pivotal hub for biotechnology innovation within the Baltic region.

Key Findings

Northway Biotech has inaugurated a state-of-the-art €61 million (approximately $65 million USD) 3,500 square meter facility in Vilnius, Lithuania, dedicated to cell therapy and personalized medicine CDMO services. This substantial investment significantly expands the company’s capabilities, incorporating up to 20 independent cGMP manufacturing lines. These lines are designed to support the production of autologous and allogeneic cell-based therapies, personalized therapeutic vaccines, and advanced 3D human tissue technologies. Strategically, Northway Biotech is positioning itself to industrialize CAR-T manufacturing and aims to integrate viral vector supply chains from its co-located gene therapy center, Celltechna, thereby offering comprehensive end-to-end solutions for advanced therapeutic product development and manufacturing.

Technical and Operational Details

Advanced cGMP Manufacturing Lines: The new facility features specialized infrastructure, including up to 20 independent cGMP manufacturing lines. This design provides robust segregation, enabling the concurrent production of diverse cell and gene therapy products. This approach minimizes cross-contamination risks and offers considerable flexibility to accommodate varied client pipelines.
Broad Therapeutic Modalities: The center is comprehensively equipped to handle a wide spectrum of advanced therapies. These include autologous (patient-specific) and allogeneic (off-the-shelf) cell-based products, personalized therapeutic vaccines, and cutting-edge technologies for 3D human tissue engineering. This versatility is crucial for addressing unmet medical needs across regenerative medicine and advanced therapeutics.
Vertical Integration Strategy: A cornerstone of Northway Biotech’s strategy is the vertical integration of viral vector supply chains. This involves leveraging its adjacent Celltechna gene therapy center to provide critical raw materials to the new cell therapy facility. This integration is designed to enhance efficiency, bolster quality control, and ensure security of supply for essential components, thereby streamlining the entire manufacturing process from vector production to the final cell product.

Strategic Significance and Outlook

This substantial investment strategically positions Northway Biotech as a critical CDMO partner within the rapidly evolving global cell and gene therapy landscape. By industrializing CAR-T manufacturing and establishing a fully integrated viral vector supply chain, the company is poised to significantly contribute to making these transformative therapies more accessible and cost-effective for patients worldwide. From an investment perspective, this move represents a strong entry into a high-growth market characterized by escalating demand for specialized manufacturing services. Economically, the facility is anticipated to generate high-skilled jobs and stimulate further growth within Lithuania’s burgeoning biotechnology ecosystem, playing a pivotal role in advancing next-generation personalized medicine.

Source: https://investlithuania.com/news/first-in-the-baltics-northway-biotech-opens-e61-million-cell-therapy-and-personalized-medicine-cdmo-in-vilnius/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.